Abstract
Pembrolizumab + chemotherapy (pembro–chemo) have shown improved OS, PFS and ORR vs chemo alone regardless of PD-L1 tumor proportion score (TPS) in patients (pts) with advanced NSCLC. This exploratory analysis presents pooled results of pembro–chemo vs chemo in East Asian pts with advanced/metastatic PD-L1–negative (ie, TPS <1%) NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
